Vaginitis due to Candida krusei

Epidemiology, clinical aspects, and therapy

Shivani Singh, Jack D. Sobel, Pallavi Bhargava, Dina Boikov, Jose Antonio Vazquez

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Twelve women with vaginal Candida krusei infection were evaluated. In vitro antifungal susceptibility testing and molecular typing were performed. Patients infected with C. krusei frequently had refractory vulvovaginal signs and symptoms that were otherwise indistinguishable from vaginitis due to other yeasts. Patients were 32-63 years old and had previously received multiple courses of antimycotic agents, including fluconazole and miconazole. The most active azole in vitro was clotrimazole, with a 90% minimum inhibitory concentration of 0.25 μg/mL. Four of 6 patients treated with boric acid had clinical and mycological cure. Two dominant genotypes of C. krusei were identified via contour-clamped homogenous electrical field analysis. No major genotypic change was observed in successive isolates from the same patient in most cases, suggesting that these refractory cases were relapses. C. krusei is a rare but important cause of refractory vaginitis and is unique because of its intrinsic resistance to fluconazole.

Original languageEnglish (US)
Pages (from-to)1066-1070
Number of pages5
JournalClinical Infectious Diseases
Volume35
Issue number9
DOIs
StatePublished - Nov 1 2002

Fingerprint

Vaginitis
Candida
Epidemiology
Fluconazole
Clotrimazole
Miconazole
Molecular Typing
Azoles
Microbial Sensitivity Tests
Therapeutics
Signs and Symptoms
Yeasts
Genotype
Recurrence
Infection
In Vitro Techniques

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Vaginitis due to Candida krusei : Epidemiology, clinical aspects, and therapy. / Singh, Shivani; Sobel, Jack D.; Bhargava, Pallavi; Boikov, Dina; Vazquez, Jose Antonio.

In: Clinical Infectious Diseases, Vol. 35, No. 9, 01.11.2002, p. 1066-1070.

Research output: Contribution to journalArticle

Singh, Shivani ; Sobel, Jack D. ; Bhargava, Pallavi ; Boikov, Dina ; Vazquez, Jose Antonio. / Vaginitis due to Candida krusei : Epidemiology, clinical aspects, and therapy. In: Clinical Infectious Diseases. 2002 ; Vol. 35, No. 9. pp. 1066-1070.
@article{c512879b17d548d3807b4c4102bb0525,
title = "Vaginitis due to Candida krusei: Epidemiology, clinical aspects, and therapy",
abstract = "Twelve women with vaginal Candida krusei infection were evaluated. In vitro antifungal susceptibility testing and molecular typing were performed. Patients infected with C. krusei frequently had refractory vulvovaginal signs and symptoms that were otherwise indistinguishable from vaginitis due to other yeasts. Patients were 32-63 years old and had previously received multiple courses of antimycotic agents, including fluconazole and miconazole. The most active azole in vitro was clotrimazole, with a 90{\%} minimum inhibitory concentration of 0.25 μg/mL. Four of 6 patients treated with boric acid had clinical and mycological cure. Two dominant genotypes of C. krusei were identified via contour-clamped homogenous electrical field analysis. No major genotypic change was observed in successive isolates from the same patient in most cases, suggesting that these refractory cases were relapses. C. krusei is a rare but important cause of refractory vaginitis and is unique because of its intrinsic resistance to fluconazole.",
author = "Shivani Singh and Sobel, {Jack D.} and Pallavi Bhargava and Dina Boikov and Vazquez, {Jose Antonio}",
year = "2002",
month = "11",
day = "1",
doi = "10.1086/343826",
language = "English (US)",
volume = "35",
pages = "1066--1070",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Vaginitis due to Candida krusei

T2 - Epidemiology, clinical aspects, and therapy

AU - Singh, Shivani

AU - Sobel, Jack D.

AU - Bhargava, Pallavi

AU - Boikov, Dina

AU - Vazquez, Jose Antonio

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Twelve women with vaginal Candida krusei infection were evaluated. In vitro antifungal susceptibility testing and molecular typing were performed. Patients infected with C. krusei frequently had refractory vulvovaginal signs and symptoms that were otherwise indistinguishable from vaginitis due to other yeasts. Patients were 32-63 years old and had previously received multiple courses of antimycotic agents, including fluconazole and miconazole. The most active azole in vitro was clotrimazole, with a 90% minimum inhibitory concentration of 0.25 μg/mL. Four of 6 patients treated with boric acid had clinical and mycological cure. Two dominant genotypes of C. krusei were identified via contour-clamped homogenous electrical field analysis. No major genotypic change was observed in successive isolates from the same patient in most cases, suggesting that these refractory cases were relapses. C. krusei is a rare but important cause of refractory vaginitis and is unique because of its intrinsic resistance to fluconazole.

AB - Twelve women with vaginal Candida krusei infection were evaluated. In vitro antifungal susceptibility testing and molecular typing were performed. Patients infected with C. krusei frequently had refractory vulvovaginal signs and symptoms that were otherwise indistinguishable from vaginitis due to other yeasts. Patients were 32-63 years old and had previously received multiple courses of antimycotic agents, including fluconazole and miconazole. The most active azole in vitro was clotrimazole, with a 90% minimum inhibitory concentration of 0.25 μg/mL. Four of 6 patients treated with boric acid had clinical and mycological cure. Two dominant genotypes of C. krusei were identified via contour-clamped homogenous electrical field analysis. No major genotypic change was observed in successive isolates from the same patient in most cases, suggesting that these refractory cases were relapses. C. krusei is a rare but important cause of refractory vaginitis and is unique because of its intrinsic resistance to fluconazole.

UR - http://www.scopus.com/inward/record.url?scp=0036827785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036827785&partnerID=8YFLogxK

U2 - 10.1086/343826

DO - 10.1086/343826

M3 - Article

VL - 35

SP - 1066

EP - 1070

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 9

ER -